# Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma

> **NCT00176800** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 69 (actual)

## Conditions studied

- Esophageal Carcinoma

## Interventions

- **DRUG:** Tetrathiomolybdate (TM)
- **PROCEDURE:** Radiation
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT00176800
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2006-02
- **Final completion:** 2013-05
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2016-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00176800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00176800, "Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00176800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*